Factors related to successful treatment of drug-resistance tuberculosis in H. Adam Malik hospital, Medan, Indonesia

S M P F Manurung¹, P Siagian¹, B Y M Sinaga¹,² and E Mutiara²

¹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Kampus USU Padang Bulan 20155, Medan, Indonesia
²Faculty of Public Health, Universitas Sumatera Utara, Kampus USU Padang Bulan 20155, Medan, Indonesia
*Corresponding author: bintang@usu.ac.id

Abstract. The number of drug-resistant TB cases keeps increasing for over the years. Drug-resistant TB is a difficult case because of the treatment, many side effects, more expensive, and less satisfactory results. This study is a retrospective cohort design aimed to determine the factors influencing the success of TB drug resistance treatment at H. Adam Malik Hospital during 2012–2015. The number of confirmed patients with drug-resistant TB was 223 people, 153 male, and 70 female. Two factors have been found to affect the treatment outcomes significantly, age and resistance pattern (P<0.05). Patients aged <50 years old have 2.73 times greater chance of recovery than patients aged ≥50 years old. Based on resistance pattern, patients with rifampicin resistant or poly-resistant would be 6.4 times more likely to recover compared with pre-XDR patients. There was no significant difference in the success rate of treatment among MDR patients compared with rifampicin resistant or poly-resistant cases. Age and resistance pattern has been proved to influence the success of drug-resistant TB treatment.

1. Introduction
Multidrug-resistant tuberculosis (MDR-TB) is a growing problem that threatens public health worldwide.[1] And tuberculosis (TB) become a leading cause of morbidity and ranks among the ten most common causes of death worldwide.[2] According to World Health Organization (WHO) report in 2014, globally 5% of TB cases are thought to become MDR-TB. The drug resistance surveillance data shows an estimated 480,000 MDR-TB patients with 210,000 deaths.[3]

The management of MDR-TB is more complicated and requires more attention than non-resistant TB management. The treated TB patients are four times more likely to develop resistance and ten times being the incidence of MDR-TB. Although in the five most countries with MDR-TB patients have a successful treatment rate of ≥ 70% but globally only 52%.[2,4,5]

According to data at H. Adam Malik Hospital, Medan, in 2015 there were 142 patients with drug-resistant TB and in 2016 were 219 patients. While the number of MDR-TB patients in Indonesia in 2015 was 1896 cases and in 2016 were 2,731 cases. It shows an increase and shows that the problem of drug-resistant TB in Indonesia remains a serious problem.[6,7]

Therefore, we are interested in identifying factors affecting the success rate of drug-resistant TB treatment.
2. Method
It was an analytic study with a retrospective cohort design aimed to determine the factors that influence the success of TB drug resistance treatment at H. Adam Malik Hospital. Data collection is done retrospectively, starting from April to August 2017. The population in this study was the data of all drug-resistant TB patients who had received MDR-TB treatment from 2012–2015.

The inclusion criteria were tuberculosis patients with a complete medical record, which has been stated as a case of drug resistance as evidenced by the results of the GeneXpert and or drug sensitivity test (DST) and patients who had received the MDR drugs. While the exclusion criteria were patients, who do not want to continue the treatment. Data collection was in total sampling from all medical records of patients treated at MDR-TB Clinic H. Adam Malik Hospital year 2012–2015. To identify factors that influence the success of treatment was by chi-square test and logistic regression. Factors studied include gender, age, resistance pattern, comorbid, and conversion time.

3. Results
This study involved 223 drug-resistant TB patients. The demographic characteristics of the patients can be seen in table 1. Based on gender, the majority of patients were 153 male (68.6%). The youngest age is 14 years old, and the oldest was 73 years old. The mean age was 42.1 ± 11.9 years old.

| Table 1. Characteristic demographic of the study. |
|-----------------------------------------------|
| Sample | n | % |
| Sex     |    |   |
| Male    | 153 | 68.6 |
| Female  |  70 | 31.4 |
| < 20 years |  1 | 0.44 |
| Age     |    |   |
| 20 - 29 years |  37 | 16.6 |
| 30 - 39 years |  59 | 26.5 |
| 40 - 49 years |  59 | 26.5 |
| 50 - 59 years |  51 | 22.9 |
| 60 - 69 years |  15 |  6.7 |
| ≥ 70 years |  1 | 0.4 |

All patients were examined by GeneXpert MTB/Rif first with MTB (+) rifampicin resistant results. Then patients examined sputum culture and drug sensitivity test (DST) to determine other types of drug resistance, classified into rifampicin resistant (RR), poly-resistant, MDR, pre-XDR, and XDR-resistant. Table 2 shows that of the 223 patients, the majority of patients were MDR-TB patients, 168 patients (75.3%), 31 patients (13.9%) were rifampicin resistant (RR), and 19 patients (8.5%) pre-XDR. As for the characteristics of the subjects based on the predicted criteria of MDR, found that the most were 6th criteria (recurrent cases of TB patients) are 46 patients (20.6%). Of all the subjects, 39 patients (17.5%) were MDR-TB patients with comorbid diabetes mellitus, and only one patient is a TB patient with HIV comorbid. All patients received treatment of drug-resistant TB in according to the guidelines for the treatment of drug-resistant TB that prepared by the Ministry of Health of Indonesia.

| Table 2. Characteristics of research samples based on resistance patterns. |
|-----------------------------------------------|
| Sample | n | % |
| Type of Resistance |    |   |
| RR       | 31 | 13.9 |
| Poly-resistant |  5 |  2.2 |
| MDR      | 168 | 75.3 |
| Pre XDR  | 19 |  8.5 |
Table 3. Characteristics of research samples based on successful treatment.

| Parameter                  | Total |
|----------------------------|-------|
|                            | n     | %    |
| Results                    |       |      |
| Cured                      | 107   | 48.0 |
| Stop treatment             | 66    | 29.6 |
| Complete treatment         | 2     | 0.9  |
| Death                      | 42    | 18.8 |
| Failed                     | 2     | 0.9  |
| Not evaluated/ moved       | 4     | 1.8  |
| Conversion Time            |       |      |
| 0-2 month                  | 103   | 46.2 |
| 3-4 month                  | 54    | 24.2 |
| 5-6 month                  | 10    | 4.5  |
| 7-8 month                  | 2     | 0.9  |
| Failed conversion          | 2     | 0.9  |
| Death before conversion    | 52    | 23.3 |
| Death                      |       |      |
| 0-2 month                  | 14    | 33.3 |
| 3-6 month                  | 15    | 35.7 |
| 7-12 month                 | 8     | 19.0 |
| 13 month – end treatment   | 5     | 11.9 |

In table 3 above, out of 223 subjects, 107 people (48%) completed medication until the end and were stated cured. A total of 66 patients (29.6%) did not complete treatment and loss to follow up. Overall only 2 (0.9%) patients who did not experience acid-fast bacilli (AFB) smear conversion at the end of treatment, and declared failed case.

Characteristics of the study subjects based on conversion time, 103 patients (46.2%) had undergone conversion within the first two months of treatment, and a total of 52 patients (23.3%) had died before the patient experienced sputum smear conversion.

The highest mortality rate found in the first six months of treatment. In general, the number of subjects that died in this study was 42 patients (18.8%).

To identify any factors contributing to the success of drug-resistant TB treatment, a statistical analysis of the results in table 4.

Table 4. Factors that affect the success of treatment.

| Parameter | Failed/Death | Healed | p-value | OR   | 95%CI |
|-----------|--------------|--------|---------|------|-------|
| Sex       |              |        |         |      |       |
| Man       | 34           | 77.3   | 71      | 65.1 | 0.14* | 0.55  | 0.24-1.23 |
| Woman     | 10           | 22.7   | 38      | 34.9 |       |       |         |
| Age       |              |        |         |      |       |
| < 50      | 26           | 59.1   | 87      | 79.8 | 0.008*| 2.73  | 1.27-5.86|
| ≥ 50      | 18           | 40.9   | 22      | 20.2 |       |       |         |
### Table 4: Treatment Outcome based on Resistance Type and Comorbid Disease

| Resistance Type | RR/Poly-resistant | MDR | Pre-XDR | Comorbid Status | Without Comorbid | With Comorbid | Conversion Time |
|----------------|------------------|-----|---------|-----------------|------------------|--------------|----------------|
| Age (years)    | 6.8              | 78.0| 6.4     |                 | 86.4            | 13.6         | 1-2 month      |
| Age (years)    | 17              | 6.4 | 19      |                 | 88              | 88           | 3-4 month      |
| Age (years)    | 15.6             | 6.4 | 17.4    |                 | 80.7            | 6.4          | 5-6 month      |
| Age (years)    | 1               | 6.4 | 6.4     |                 | 0.04            | 0.53         | No Conversions |
| Age (years)    | 1               | 6.4 | 0.9     |                 | 2.2             | 0.73         |                |
| Age (years)    | 2               | 6.4 | 0.9     |                | 0.60-8.01       | 0.27-1.97   |

*Chi-Square Test

Logistic Regression Test

Table 4 shows two things that significantly affect the treatment outcome, i.e., age and resistance type (P<0.05). While the gender, comorbid disease, and conversion time variables were not proven to affect the success of treatment.

Patients with aged <50 years old will have 2.73 times greater chance of recovery than patients aged ≥50 years old.

Based on resistance pattern, rifampicin resistant or poly-resistant patients would be 6.4 times more likely to be cured compared to pre-XDR patients. However, there was no significant difference in the success rate of treatment among MDR patients compared with rifampicin resistant and poly-resistant cases.

### 4. Discussion

This study found the factors that have been shown to influence the success of treatment are age and resistance pattern. While gender, comorbid disease and conversion time were not proven to affect the success of treatment.

The amount of success rate treatment in this study reached 48%. Means that the number of patients declared cured is not up to half of the total number of patients. This result shows that not too different from other centers as listed in table 5.[5,8,9]

**Table 5. Comparison of the success rate of drug-resistant TB treatment.**

| Researchers     | Place              | Year     | Successful Rate |
|-----------------|--------------------|----------|-----------------|
| Manurung et al  | Medan, Indonesia   | 2012-2015| 48%             |
| Tirtana         | Semarang, Indonesia| 2011     | 40%             |
| Marais et al    | South Africa       | 2013-2014| 48.8%           |
| WHO             | Global             | 2016     | 52%             |

Marais et al. found that poly-resistant and rifampicin resistant had no significant difference in success rates. Additional resistance to Ethambutol and streptomycin does no effect on the success of MDR-TB treatment compared with patients who are resistant only to rifampicin and isoniazid.[8]

Means that as long as the drug-resistant TB patients obtain the appropriate therapeutic regimen, the success rate is not much different from that of patients diagnosed with rifampicin resistant and poly-resistant. However, patients with pre-XDR TB still have a risk of treatment failure when compared with rifampicin resistant and poly-resistant patients.

This study also revealed that comorbid disease (DM and HIV) did not affect the success rate of drug-resistant TB patients (p>0.05). It also found by research conducted by Marais et al., who stated that HIV incidence did not have a significant effect on the success rate of drug-resistant TB patients.[8]
5. Conclusion
The success rate of drug-resistant TB treatment in H. Adam Malik Hospital from 2012–2015 is 48%. Age and resistance pattern proved to influence the success of drug-resistant TB treatment (p<0.05), while gender, comorbidity and conversion time did not significantly (p>0.05).

References
[1] World Health Organization 2011 Drug-resistant tuberculosis in south-east Asia region: Status report (Geneva, Switzerland)
[2] Lange C, Abubakar I, Alffenaaar J W C, et al. 2014 Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement Eur. Respir. J. 44 23-63
[3] World Health Organization 2015 Global tuberculosis report (Geneva, Switzerland)
[4] World Health Organization 2008 Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 (Geneva, Switzerland)
[5] World Health Organization 2016 Global tuberculosis report 2016 (Geneva, Switzerland)
[6] Siagian P 2017 How to diagnose and manage MDR-TB Faculty of Medicine, Universitas Sumatera Utara: update on current management in daily practice
[7] Nurjannah 2017 Update kegiatan program TB (Kementerian Kesehatan RI: Monev TB)
[8] Marais E, Mlambo C K, Lewis J J, et al. 2014 Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa Infection 42 405-13
[9] Tirtana B T 2011 Faktor-faktor yang mempengaruhi keberhasilan pengobatan pada pasien tuberkulosis paru dengan resistensi obat tuberkulosis di wilayah Jawa Tengah (Faculty of Medicine: Universitas Diponegoro)